marinedrugs Marine Drugs Mar. Drugs Marine Drugs 1660-3397 MDPI 10.3390/md10061244 marinedrugs-10-01244 Review Conotoxins that Confer Therapeutic Possibilities Essack Magbubah Bajic Vladimir B. Archer John A. C. * Computational Bioscience Research Center (CBRC), King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Jeddah, Kingdom of Saudi Arabia; Email: magbubah.essack@kaust.edu.sa (M.E.); vladimir.bajic@kaust.edu.sa (V.B.B.) Author to whom correspondence should be addressed; Email: john.archer@kaust.edu.sa; Tel.: +966-544-700-701; Fax: +966-2-802-0127. 04 06 2012 06 2012 10 6 1244 1265 06 02 2012 24 04 2012 24 05 2012 © 2012 by the authors; licensee MDPI, Basel, Switzerland. 2012

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Cone snails produce a distinctive repertoire of venom peptides that are used both as a defense mechanism and also to facilitate the immobilization and digestion of prey. These peptides target a wide variety of voltage- and ligand-gated ion channels, which make them an invaluable resource for studying the properties of these ion channels in normal and diseased states, as well as being a collection of compounds of potential pharmacological use in their own right. Examples include the United States Food and Drug Administration (FDA) approved pharmaceutical drug, Ziconotide (Prialt®; Elan Pharmaceuticals, Inc.) that is the synthetic equivalent of the naturally occurring ω-conotoxin MVIIA, whilst several other conotoxins are currently being used as standard research tools and screened as potential therapeutic drugs in pre-clinical or clinical trials. These developments highlight the importance of driving conotoxin-related research. A PubMed query from 1 January 2007 to 31 August 2011 combined with hand-curation of the retrieved articles allowed for the collation of 98 recently identified conotoxins with therapeutic potential which are selectively discussed in this review. Protein sequence similarity analysis tentatively assigned uncharacterized conotoxins to predicted functional classes. Furthermore, conotoxin therapeutic potential for neurodegenerative disorders (NDD) was also inferred.

 Conus cone snail peptide neuropeptide conotoxin nicotinic acetylcholine receptor sodium channel calcium channel potassium channel 1. Introduction

Cone Snails (genus Conus) are invertebrate venomous predators comprising approximately 700 species [1], with each Conus species producing a distinctive repertoire of 100–200 venom peptides [2]. The venom peptides are used to immobilize and digest prey as well as to defend cone snails from predators. It has been demonstrated that most Conus peptides potently and specifically target the voltage- and ligand-gated ion channels in the nervous systems of prey. These Conus peptides also act on homologous mammalian ion channels due to the degree of structural conservation exhibited by the voltage- and ligand-gated ion channels across higher eukaryotes. Moreover, mammalian ion channels exhibit diverse tissue expression patterns. This difference in tissue expression patterns was demonstrated with conotoxins that target the nicotinic acetylcholine receptor (nAChR) subtypes present at the invertebrate neuromuscular junctions which, while not present in vertebrate neuromuscular junctions, are expressed in tissues relevant to pain. Thus peptides that target these ion channels may potentially be analgesic therapeutic agents in vertebrates [3].

Conus peptides, such as the μ-conotoxins and ω-conotoxins, are currently being used as standard research tools in neuroscience. The μ-conotoxins are used for the immobilization of skeletal muscles without affecting axonal or synaptic events because of their ability to block the muscle Na+ channel Nav1.4, but not axonal Na+ channels Nav1.1–Nav1.3 and Nav1.6–Nav1.9 [4,5]. The ω-conotoxins are used as standard pharmacological reagents in voltage-gated calcium (Ca2+) channel-related research and are used to block neurotransmitter release [6,7]. ω-conotoxins have also been used to diagnose the Ca2+ channel targeted disease, Lambert-Eaton myasthenic syndrome [8]. Moreover, Ziconotide (Prialt®; Elan Pharmaceuticals, Inc.) is the first United States Food and Drug Administration (FDA) approved cone snail-derived pharmaceutical drug. Ziconotide is a synthetic equivalent of a naturally occurring conopeptide known as SNX-111 or ω-conotoxin MVIIA that was isolated from the cone snail, Conus magus [3]. This ω-conotoxin MVIIA targets the N-type Ca2+ channels that are related to algesia in the nervous system and is thus being used for the treatment of severe chronic pain in patients requiring intrathecal (IT) administration of drugs [9].

Other cone snail-derived peptides such as CGX-1007, CGX1160, CGX-1051, ACV1 and Xen2174, are now being tested in clinical trials. CGX-1007 (Conantokin G) isolated from the cone snail, Conus geographus, is a N-methyl-D-aspartate (NMDA) receptor antagonist that is being screened as a potential treatment for epileptic seizures [10]. CGX1160 (Contulakin-G) also isolated from Conus geographus [11], is a neurotensin subtype 1 (NTS1) receptor agonist that is being screened as a potential treatment of severe chronic pain in patients requiring IT administration of drugs [12]. CGX-1051 isolated from the cone snail, Conus purpurasens, is a potassium (K+) channel inhibitor that is being screened as a potential treatment for heart myocardial infarction [13]. ACV1 (conotoxin Vc1.1) identified from the cone snail, Conus victoriae is a neuronal nAChR antagonist that is in multiple trials as a potential treatment for sciatic neuropathic pain and diabetic neuropathy or post herpetic neuralgia [14]. Xen2174 (Mr1A) isolated from the cone snail, Conus marmoreus, is also a nAChR antagonist that is being screened as a potential treatment for chronic neuropathic [15] and post-surgical pain [16]. In addition, a plethora of Conus peptides have been demonstrated to: (1) induce antinociceptive [17], antiepileptic [18], neuroprotective or cardioprotective activities [19,20]; and (2) have potential relevance in cancer [21] and neuronal diseases [22,23].

In light of these encouraging reports of conotoxin-related research, here we review recently isolated Conus peptides that may have the potential to be developed into therapeutic drugs. We used the National Center for Biotechnology Information (NCBI) PubMed database [24] to search for cone snail derived lead compounds using the following keywords: “Conus OR cone snail OR conotoxin OR conopeptide”.

This query was limited to articles published from 1 January 2007 to 31 August 2011, so as to include only recently isolated Conus peptides. This yielded a total of 1129 documents, curation of which allowed for the identification of 98 Conus peptides that have potential to be used to generate new drugs. Here we present an overview of the 98 conotoxins that have been reported in literature from 1 January 2007 to 31 August 2011, correlated with the conotoxins cysteine arrangement and their known targets (Figure 1). The compounds identified constitute five phenotypic classes: (1) 14 nAChR inhibitors; (2) 10 Na+ channel inhibitors; (3) 2 Ca2+ channel inhibitors; (4) 2 K+ channel inhibitors; and (5) 70 peptides with targets that have not been defined (Supplementary Table S1).

Peptides isolated from cone snails since the 1 January 2007 to 31 August 2011, categorized by their respective targets.

 2. <italic>Conus</italic> Peptides That Exhibit Therapeutic Potential 2.1. Voltage-Gated Ion Channels Targeted by Conotoxins

Of the conotoxins highlighted in this review, 14% (14/98) have been demonstrated to inhibit the Na+, Ca2+ or K+ channels. These are transmembrane proteins that mediate the excitability of nerve and muscle cells. To date, nine mammalian Na+ channel α subunits (Nav1.1–Nav1.9) have been identified and characterized with respect to sensitivity to the neurotoxin tetrodotoxin (TTX) [5]. These Na+ channels are modulated by numerous natural toxins, either by blocking current through the pore or by modifying channel gating [25]. Na+ channel subtypes Nav1.8 and Nav1.9 have been characterized as being tetrodotoxin-resistant (TTX-R) and are implicated in neuropathic pain states [26]. On the other hand, Na+ channel subtypes Nav1.7, Nav1.3, Nav1.2 and Nav1.1 are tetrodotoxin-sensitive (TTX-S) and implicated in neuropathic pain [27], inflammation [26] and epilepsy [28,29]. Similarly, more than 40 known human K+ channel α subunits have been identified and implicated in numerous disorders [30]. Some examples are: (1) Kv7 has been implicated in cerebral vasospasm [31]; (2) Kv1.4 has been implicated in trigeminal inflammatory allodynia in temporomandibular joint (TMJ) disorder [32]; (3) Kv1.2, Kv1.3 and Kv1.6 have been shown to be key regulators in Dopamine release, the dysfunction of which is thought to be implicated in drug abuse and in diseases such as schizophrenia and Parkinson’s disease [33]; (4) Kv1.3 has also been shown to a target for immunosuppression [34]; (5) Kv2.1 has been implicated in hypoxia/anoxia induced cell apoptosis [35] and diabetes [36] and; (6) mutations in Kv1.1 have been implicated in autosomal dominant hypomagnesemia and episodic ataxia type 1 [37]. Ten Ca2+ channel subtypes have also been identified (Cav1.1, Cav1.2, Cav1.3, Cav1.4, Cav2.1, Cav2.2, Cav2.3, Cav3.1, Cav3.2 and Cav3.3) and implicated in numerous disorders too. Some examples are: (1) Cav2.1 (P/Q type) and Cav2.2 (N-type) have been implicated in bladder nociception [38]; (2) Cav1.3 (L-type) has been implicated in Parkinson’s disease [39]; (3) Cav3.1, Cav3.2 and Cav3.3 (T-type) have been implicated in age-related neurodegenerative disorders [40]; and (4) Cav2.3 (R-type) has been implicated in diabetes [41]. To understand the function of voltage-gated ion channel subtypes in the normal and disease states will require novel inhibitors with improved voltage-gated ion channel subtype selectivity.

2.1.1. Na<sup>+</sup> Channel Inhibitors

Lt5d: Liu et al. (2007) isolated the novel conotoxin, Lt5d, from the venom of Conus litteratus [42]. Lt5d was identified as a T-1-conotoxin comprising 12 amino acid residues with a characteristic arrangement of four-cysteine residues (-CC-CC-) (Table 1). It was further demonstrated that Lt5d inhibit tetrodotoxin-sensitive (TTX-S) sodium currents on adult rat dorsal root ganglion (DRG) neurons (IC50 156.16 nM), but has no effect on tetrodotoxin-resistant (TTX-R) sodium currents treated with 150 nM Lt5d [42]. Thus, Lt5d is the first T-1-conotoxin shown to inhibit TTX-S Na+ channels.

Lt6c: Wang et al. (2008) isolated Lt6c from the venom of Conus litteratus as well [43]. Lt6c was shown to comprise 28 amino acid residues with a characteristic arrangement of the six-cysteine residues (-C-C-CC-C-C-) (Table 1). It was further demonstrated that 800 nM Lt6c inhibits both the TTX-S and TTX-R sodium currents on adult rat DRG neurons [43].

marinedrugs-10-01244-t001_Table 1

Amino acid sequence and conserved cysteine residues of the recently identified Na+ channel targeting conotoxins.

Peptide AA Sequence Gene Family with Cysteine Framework and Residues Targets Has no Effect on Reference
Lt5d DCCPAKLLCCNP T superfamily V [connectivity I–III, II–IV] -CC-CC- Na+ channel ND [42]
Lt6c WPCKVAGSPCGLVSECCGTCNVLRNRCV O1 superfamily VI/VII [connectivity I–IV, II–V, III–VI] -C-C-CC-C-C- Na+ channel ND [43]
TIIIA RHGCCKGOKGCSSRECRPQHCC M superfamily III -CC-C-C-CC- rNav1.2 rNav1.4 rNav1.3 rNav1.5 rNav1.7 rNav1.8 [44]
Cal12a DVCDSLVGGHCIHNGCWCDQEAPHGNCCDTDGCTAAWWCPGTKWD O2 superfamily XII -C-C-C-C-CC-C-C- Na+ channel ND [45]
Cal12b DVCDSLVGGHCIHNGCWCDQDAPHGNCCDTDGCTAAWWCPGTKWD O2 superfamily XII -C-C-C-C-CC-C-C- Na+ channel ND [45]
BuIIIA VTDRCCKGKRECGRWCRDHSRCC M superfamily III -CC-C-C-CC- Nav1.4 ND [46]
BuIIIB VGERCCKNGKRGCGRWCRDHSRCC M superfamily III -CC-C-C-CC- Nav1.4 ND [46]
BuIIIC IVDRCCNKGNGKRGCSRWCRDHSRCC M superfamily III -CC-C-C-CC- Nav1.4 ND [46]
SIIIA ZNCCNGGCSSKWCRDHARCC M superfamily III -CC-C-C-CC- rNav1.2 rNav1.4 rNav1.3 rNav1.5 rNav1.7 rNav1.8 [47]
SIIIB ZNCCNGGCSSKWCKGHARCC M superfamily III -CC-C-C-CC- rNav1.2 rNav1.4 rNav1.3 rNav1.5 rNav1.7 rNav1.8 [47]

ND = no data.

TIIIA: Lewis et al. (2007) isolated the novel conotoxin, TIIIA, from the venom of Conus tulipa [44]. TIIIA was identified as a μ-conotoxin comprising 22 amino acid residues with a characteristic arrangement of the six-cysteine residues (-CC-C-C-CC-) (Table 1). TIIIA was further demonstrated to inhibit Na+ channel subtype rNav1.2 (IC50 of 40 nM) and rNav1.4 (IC50 of 9 nM). Moreover, no effect was demonstrated on the Na+ channel subtypes rNav1.3, rNav1.5, rNav1.7 and rNav1.8 induced with 3 μM TIIIA. Also, the TIIIA analog [E15A]TIIIA (IC50 of 15 pM) had a 10-fold higher affinity than TIIIA (IC50 of 148 pM) for TTX-S Na+ channels [44].

Cal12a and Cal12b: Gilly et al. (2011) isolated two novel conotoxins, Cal12a and Cal12b, from the venom of Conus Californicus [45]. Both Cal12a and Cal12b were identified as μ-conotoxins comprising 45 amino acid residues with eight-cysteine residues in framework 12 (-C-C-C-C-CC-C-C-) (Table 1). It was further demonstrated that Cal12a and Cal12b reversibly block the Na+ channels on giant-fiber-lobe (GFL) neurons, but have no effect on Ca2+ and K+ channels [45].

BuIIIA, BuIIIB and BuIIIC: Holford et al. (2009) identified the novel conotoxins BuIIIA, BuIIIB and BuIIIC, by cDNA cloning and peptide purification from Conus bullatus. BuIIIA, BuIIIB and BuIIIC were also identified as μ-conotoxins have a characteristic arrangement of six-cysteine residues (-CC-C-C-CC-) and comprising 23, 24 and 26 amino acid residues, respectively (Table 1). Activities of these compounds were compared to a representative set of μ-conotoxins, PIIIA, GIIIA, and KIIIA. BuIIIA and KIIIA were demonstrated to reversibly block the Na+ channel skeletal muscle subtype Nav1.4 with similar potency. In contrast, BuIIIB and BuIIIC were demonstrated to be more potent irreversible inhibitors of the Na+ channel subtype Nav1.4, similar to the reversible inhibitors of Nav1.4, PIIIA and GIIIA [46]. The novel structural determinants of BuIIIA, BuIIIB, and BuIIIC along with their ability to potently inhibit Nav1.4 make these conotoxins useful in defining features of the Nav1.4 pharmacophore and thereby facilitate the design of highly subtype-specific ligands that target Nav1.4.

SIIIA and SIIIB: Schroeder et al. (2008) isolated the novel conotoxins, SIIIA and SIIIB, from the venom of Conus striatus [47]. Both SIIIA and SIIIB were identified as μ-conotoxin comprising 20 amino acid residues with a characteristic arrangement of six-cysteine residues (-CC-C-C-CC-) (Table 1). SIIIB was further demonstrated to inhibit Na+ channel subtype rNav1.2 (IC50 of 5 nM) and rNav1.4 (IC50 of 3 nM) more potently than SIIIA (rNav1.2: IC50 of 10 nM and rNav1.4: IC50 of 60 nM). However, SIIIA is the more selective ligand for rNav1.2 as it has a high potency for rNav1.2 and also shows a larger difference in IC50 between rNav1.2 and rNav1.4. Furthermore, Xenopus oocytes treated with 3 μM SIIIA and SIIIB showed little to no effect on Na+ channel subtypes Nav1.3, Nav1.5, Nav1.7 and Nav1.8 [47].

2.1.2. Ca<sup>2+ </sup>Channel Inhibitors

FVIA: Lee et al. (2010) identified the novel conotoxin, FVIA, by cDNA cloning and peptide purification from Conus fulmen. FVIA was identified as a ω-conotoxin comprising 25 amino acid residues with a characteristic arrangement of six-cysteine residues (-C-C-CC-C-C-) (Table 2). FVIA activity was compared to the known Ca2+ channel inhibitor, MVIIA. Both FVIA (IC50 of 11.5 nM) and MVIIA (IC50 of 7.96 nM) were shown to inhibit human N-type Ca2+ channels stably expressed in HEK293 cells (C2D7 cells), but FVIA shows greater reversibility than MVIIA. FVIA was further demonstrated to have no effect on other Ca2+ channels (T-type and P/Q-type) and TTX-sensitive Na+ channels of mouse DRG neurons [48].

CalTx: Bernaldez et al. (2011) isolated novel conotoxin, CalTx, from the venom of Conus californicus as well [49]. CalTx was shown to comprise 13 amino acid residues with a characteristic arrangement of four-cysteine residues (-C-C-CC-) (Table 2). In contrast to Cal12a and Cal12b that show no effect on Ca2+ channels, CalTx was further demonstrated to reversibly block calcium current in rat DRG neurons treated with 20 μM CalTx [49].

marinedrugs-10-01244-t002_Table 2

Amino acid sequence and conserved cysteine residues of the recently identified Ca2+ channel targeting conotoxins.

Peptide AA Sequence Gene Family with Cysteine Framework and Residues Targets Has no Effect on Reference
CalTx NCPAGCRSQGCCM XVI -C-C-CC- N-type L-type P/Q-type R-type T-type [49]
FVIA CKGTGKSCSRIAYNCCTGSCRSGKC O1 superfamily VI/VII [connectivity I–IV, II–V, III–VI] -C-C-CC-C-C- N-type T-type P/Q-type TTX-S Na+ channel [48]
2.1.3. K<sup>+</sup> Channel Inhibitors

Sr11a: Aguilar et al. (2007) isolated the novel conotoxin, Sr11a, from the venom of Conus spurius. Sr11a was identified as a I-conotoxin comprising 22 amino acid residues with a characteristic arrangement of six-cysteine residues (-CC-CC-C-C-) (Table 3) [50]. In 2010, it was further demonstrated that Sr11a inhibits the K+ channel subtype Kv1.2 (IC50 of 66 nM) and Kv1.6 (IC50 of 58 nM), but shows no effect on Kv1.3 treated with up to 10 Mm Sr11a [51].

marinedrugs-10-01244-t003_Table 3

Amino acid sequence and conserved cysteine residues of the recently identified K+ channel targeting conotoxins.

Peptide AA Sequence Gene Family with Cysteine Framework and Residues Targets Has no Effect on Reference
Sr11a NQQCCWRSCCRGECEAPCRFGP I2 superfamily XI [connectivity I–IV, II–VI, III–VII, V–VIII] -CC-CC-C-C- Kv1.2 Kv1.6 Kv1.3 [50,51]
RIIIj LPPCCTPPKKHCPAPACKYKPCCKS M superfamily III -CC-C-C-CC- Kv1.2 Kv1.1 Kv1.3 Kv1.4 Kv1.5 Kv1.6 KCNQ2/KCNQ3 BK [20]

RIIIJ: Chen et al. (2010) isolated the novel conotoxin, RIIIJ, from the venom of Conus radiatus. RIIIJ was identified as a κM-conotoxin comprising 25 amino acid residues with a characteristic arrangement of six-cysteine residues (-CC-C-C-CC-) (Table 3). The activity of this compound was compared to the known K+ channel inhibitor, RIIIK. RIIIJ (IC50 of 33 nM) was shown to reversibly inhibit the K+ channel subtype Kv1.2 with a higher potency than RIIIK (IC50 of 352 nM). Both RIIIJ and RIIIK showed very low or no affinity for K+ channel subtype Kv1.1, Kv1.3, Kv1.4, Kv1.5, Kv1.6, KCNQ2/KCNQ3 and BK [20].

 2.2. Ligand-Gated Ion Channels Targeted by Conotoxins

This review additionally highlights that 14% (14/98) of the novel identified conotoxins are also nAChR inhibitors. nAChR respond to endogenous agonists including acetylcholine and choline and participate in an extensive range of processes including cognitive function, motor movement, sound perception and immune function. nAChRs are allosteric transmembrane proteins composed of one or more α subunits (α1–α10) either alone or in combination with one or more non-α-subunits, (β subunits (β1–β4), γ, δ or ε), that together make up the functional ligand-gated ion channel complex; all nAChRs are believed to contain five such subunits. nAChR subtypes show distinct anatomical location, unique biophysical and pharmacological properties, and additionally have been implicated in numerous disorders. Some examples are: (1) α6β2 and α4β2 has been implicated in Parkinson’s disease [52], (2) α7 has been implicated in Alzheimer’s disease [53] and schizophrenia [54] and has been identified as the target for chemotherapy-related cognitive impairment [55]; and (3) α9α10 has been identified as the target for the development of analgesics for the treatment of chronic neuropathic pain [56]. To understand the functioning of these ligand-gated ion channel subtypes in the normal and disease states requires novel inhibitors with improved ligand-gated ion channel subtype selectivity.

nAChR Inhibitors

AlphaD-cap (αD-cap) and AlphaD-mus (αD-mus): Kauferstein et al. (2009) isolated two novel conopeptides, αD-Cp and αD-Ms, from the venom of Conus capitaneus and Conus mustelinus, respectively [57]. Both αD-Cp and αD-Ms were shown to be structurally homologous to the αD-conopeptides (αD-VxXIIA, -B and -C) isolated from the venom of Conus vexillum [58], comprising 49 amino acid residues and having a characteristic arrangement of ten-cysteine residues (-C-CC-C-CC-C-C9C-C-) (Table 4). αD-Cp and αD-Ms were further demonstrated to specifically block neuronal nicotinic acetylcholine receptors (nAChRs). αD-Cp showed the same selectivity profile for the nAChR subtypes as αD-Ms, but has a lower potency. αD-Ms demonstrated selectivity for the α7 (IC50 0.12 nM), α3β2 (IC50 1.08 nM) and α4β2 (IC50 4.5 nM) neuronal nAChR subtypes. Both peptides showed no effect on the nAChR subtypes α3β4 and α4β4 and the muscle nAChR subtype α1β1γδ at concentrations up to 3 μM [57].

αC-PrXA: Jimenez et al. (2007) isolated the novel conotoxin, αC-PrXA, from the venom of Conus parius [59]. αC-PrXA is an unusual αC-conotoxin (-C-C-) comprising 32 amino acid residues (Table 4) and it is most similar in its biochemical features to snake toxin Waglerins. This compound was further demonstrated to potently block the skeletal muscle nAChR subtypes α1β1γδ (IC50 3.0 nM) and α1β1εδ (IC50 1.8 nM). Moreover, little to no effect was demonstrated on neuronal nAChRs (subtypes α7, α3β2, α3β4, α2β4, α4β2 and α9α10), NMDA receptors (subtypes NR2A and NR2B) and Na+ channels (subtypes Nav1.4 and Nav1.6) induced with 10 μM αC-PrXA [59].

PrIIIE: Lluisma et al. (2009) identified the novel conotoxin, PrIIIE, by cDNA cloning and peptide purification from Conus parius as well. PrIIIE was identified as a ψ-conotoxin comprising 24 amino acid residues (Table 4) with a characteristic arrangement of six-cysteine residues (-CC-C-C-CC-) [60], similar to ψ-conotoxins, PIIIE and PIIIF, previously isolated from Conus purpurascens [61]. It was further demonstrated that PrIIIE blocks the nAChR subtypes α1β1γδ (IC50 0.25 μM) and α1β1εδ (IC50 3.24 μM). Unlike PIIIE, PrIIIE demonstrated no effect on the Na+ channel subtype Nav1.4 induced with 5 nM PrIIIE. Moreover, PrIIIE (IC50 0.25 μM) was shown to be a significantly more potent nAChR receptor inhibitor than PIIIE (IC50 7 μM) [60].

Pu14a and Ts14a: Peng et al. (2010) identified two novel conotoxins, Pu14a and Ts14a, by cDNA cloning and peptide purification from Conus pulicarius and Conus tessulatus, respectively. Both Pu14a and Ts14a contain the characteristic arrangement of four separate cysteine residues (C-C-C-C) and additionally share high sequence similarity comprising 19 amino acid residues (Table 4). However, only Pu14a was further demonstrated to block the nAChR subtypes α3β2 (IC50 10 μM), α6α3β2 (IC50 1 μM) and α1β1γδ (IC50 1 μM). Moreover, Pu14a showed no effect on the K+ channels in mouse superior cervical ganglion neurons [62].

α-PIB: Lopez-Vera et al. (2007a) isolated the novel conotoxin, α-PIB, from the venom of Conus purpurascens [63]. α-PIB is an unusual α4/4-conotoxin (-CC-C-C-) comprising 16 amino acid residues (Table 4). This compound was further demonstrated to specifically block the skeletal muscle nAChR subtypes α1β1γδ (IC50 45 nM) and α1β1εδ (IC50 36 nM). Moreover, no effect was demonstrated on nAChR subtypes α7, α3β4, α3β2, α2β4 and α9α10 induced with 10 μM α-PIB [63].

SrIA and SrIB: Lopez-Vera et al. (2007b) isolated two novel α-conotoxins, SrIA and SrIB, from the venom of Conus spurius and synthesized the synthetic analog [γ15E]SrIB, by substituting glutamate for the γ-carboxyglutamate residue [64]. Both peptides along with [γ15E]SrIB comprise 18 amino acid residues with the typical 4/7-type framework (-CC-C-C-) (Table 4) and thus were compared to the α4/7-conotoxin EI previously isolated from the from Conus ermineus [65]. The results with [γ15E]SrIB were shown not to be significantly different from the natural compounds, thus [γ15E]SrIB was used for further testing owing to the limited availability of the natural toxins SrIA and SrIB. EI demonstrated strong blocking of the nAChR subtypes α4β2, α1β1γδ and α3β4 at 10 μΜ, whilst the novel peptides only demonstrated weak blocking of the nAChR subtypes α4β2 and α1β1γδ at the same concentration. However, SrIA, SrIB and [γ15E]SrIB induces strong potentiation of the nAChR subtypes α4β2 and α1β1γδ (IC50 1.78 nM) [64].

Ac1.1a and Ac1.1b: Yuan et al. (2007) identified novel conotoxins, Ac1.1a and Ac1.1b, by cDNA cloning and peptide purification from Conus achatinus. It was shown that Ac1.1a and Ac1.1b are α3/5 conotoxins comprising 17 amino acid residues with a characteristic arrangement of four-cysteine residues (-CC-C-C-) (Table 4) [66]. Liu et al. (2007) further demonstrated that both Ac1.1a and Ac1.1b block the nAChR subtypes α1β1γδ (Ac1.1a: IC50 35.90 nM; Ac1.1b: IC50 25.80 nM), α1β1εδ (Ac1.1a: IC50 3.20 nM; Ac1.1b: IC50 0.10 nM), α2β2 (Ac1.1a and Ac1.1b: IC50 > 5000 nM), α3β4 (Ac1.1a and Ac1.1b: IC50 > 50,000 nM) and α1γβ1 (Ac1.1a and Ac1.1b: IC50 > 50,000 nM), indicating that both toxins strongly prefer the α1-δ subunit interface instead of the α1-γ binding site on the nAChRs [67].

ArIA and ArIB: Whiteaker et al. (2007) identified the novel conotoxins, ArIA and ArIB, by cDNA cloning and peptide purification from Conus arenatus. It was shown that both ArIA and ArIB have the characteristic arrangement of four-cysteine residues (-CC-C-C-) and are α4/7 conotoxins comprising 22 and 20 amino acid residues, respectively (Table 4) [68]. These compounds were further demonstrated to specifically block the nAChR subtypes α7 and α3β2. ArIB (IC50 1.81 nM) blocked α7 more potently than ArIA (IC50 6.02 nM), whilst ArIA (IC50 18.0 nM) blocked α3β2 more potently than ArIB (IC50 60.1 nM) [68]. Taken together, ArIB is the more selective ligand for α7 nAChRs as it has a higher potency for α7 and also showed a larger difference in IC50 between α7 and α3β2 nAChRs.

α-TxIA and TxIA(A10L): Dutertre et al. (2007) isolated the novel α-conotoxin, α-TxIA, from the venom of Conus textile and synthesized its synthetic analog TxIA(A10L) [69]. Both α-TxIA and its synthetic analog TxIA(A10L) comprise 16 amino acid residues with a characteristic arrangement of four-cysteine residues (-CC-C-C-) (Table 4). These compounds were further demonstrated to block the neuronal nAChR subtypes α7 and α3β2. The α3β2 nAChR was selectively targeted by both α-TxIA (IC50 3.6 nM) and TxIA(A10L) (IC50 2.0 nM), whilst TxIA(A10L) (IC50 39 nM) blocks the α7 nAChR tenfold more potently than α-TxIA (IC50 392 nM). Moreover, both compounds exerted no effect on the α4β2 nAChR and muscle nAChR at concentrations up to 10 μM [69].

marinedrugs-10-01244-t004_Table 4

Amino acid sequence and conserved cysteine residues of the recently identified nAChR targeting conotoxins.

Peptide AA Sequence Gene Family with Cysteine Framework and Residues nAChR Targets Has no Effect on Reference
AlphaD-cap EVQECQVDTPGSSWGKCCMTRMCGTMCCSRSVCTCVYHWRRGHGCSCPG D superfamily XX -C-CC-C-CC-C-C-C-C- α7 α3β2 α4β2 α3β4 α4β4 [57]
AlphaD-mus DVRECQVNTPGSKWGKCCMTRMCGTMCCARSGCTCVYHWRRGHGCSCPG D superfamily XX -C-CC-C-CC-C-C-C-C- α7 α3β2 α4β2 α3β4 α4β4 [57]
α-PIB ZSOGCCWNPACVKNRC A superfamily I [connectivity I–III, II–IV] -CC-C-C- α1β1εδ α1β1γδ α7 α3β4 α3β2 α2β4 α9α10 [63]
SrIA RTCCSROTCRMγYPγLCG A superfamily I [connectivity I–III, II–IV] -CC-C-C- α4β2 α1β1γδ α3β4 [64]
SrIB RTCCSROTCRMEYPγLCG A superfamily I [connectivity I-III, II-IV] -CC-C-C- α4β2 α1β1γδ α3β4 [64]
Pu14a DCPPHPVPGMHKCVCLKTC A superfamily XIV [connectivity I–III, II–IV] -C-C-C-C- α3β2 α6α3β2 α1β1γδ K+ channels [62]
PrIIIE AARCCTYHGSCLKEKCRRKYCCGR M superfamily III -CC-C-C-CC- α1β1εδ α1β1γδ Nav1.4 [60]
ArIA IRDECCSNPACRVNNOHVCRRR A superfamily I [connectivity I-III, II-IV] -CC-C-C- α7 α3β2 ND [68]
ArIB DECCSNPACRVNNPHVCRRR A superfamily I [connectivity I-III, II-IV] -CC-C-C- α7 α3β2 ND [68]
Ac1.1a NGRCCHPACGKHFNCGR A superfamily I [connectivity I-III, II-IV] -CC-C-C- α1β1γδ α1β1εδ α2β2 α3β4 α1γβ1 ND [66,67]
Ac1.1b NGRCCHPACGKHFNCGR A superfamily I [connectivity I-III, II-IV] -CC-C-C- α1β1εδ α1β1γδ α2β2 α3β4 α1γβ1 ND [66,67]
PrXA TYGIYDAKPOFSCAGLRGGCVLPONLROKFKE -C-C- α1β1εδ α1β1γδ α7 α3β2 α3β4 α2β4 α4β2 α9 α10 Nav1.4 Nav1.6 NR2A NR2B [59]
α-TxIA GCCSRPPCIANNPDLC A superfamily I [connectivity I-III, II-IV] -CC-C-C- α7 α3β2 α4β2 α1β1εδ α1β1γδ [69]
TxIA(A10L) GCCSRPPCILNNPDLC A superfamily I [connectivity I-III, II-IV] -CC-C-C- α7 α3β2 α4β2 α1β1εδ α1β1γδ [69]

ND = no data.

 3. Prediction of Conotoxin Targets

By determining their protein sequence similarities, and potential number of disulfide bridges and the types of cysteine arrangement of conotoxins with known targets to the 70 conotoxins with undetermined targets using Blastp [70], we predicted the targets of the conotoxins whose targets are currently not defined (Supplementary Table S1). Multiple alignments of Blastp results discussed in this review are presented using ClustalW2 [71]. Thus conotoxin targets are inferred based on sequence similarity. Targets could not be predicted for all conotoxins as some conotoxins such as Ca11a (I3 superfamily), Ca11b (I3 superfamily), Ca8a (S superfamily), Vi15a (V superfamily) and Ca16a (Y superfamily) belong to newly defined gene superfamilies, whilst others such as Mr1e have not been assigned to a gene superfamily as yet. Also, I2 superfamily conotoxins such as Eb12.4, Im12.10, Mr12.5, Mr12.8, Lt12.4, Lt12.9 and TxX sequence similarity infer that they may have a similar target but there are currently no known targets for conotoxins of this type (Supplementary Figure S1). Similarly, conotoxins Pr3a, Ar11a, Qc16a, Pu5.2, Sr7a, Pr6a, Pr6b, Pr6c, Pr6d and Pu5.3 also show no significant sequence similarity to conotoxins with known targets.

However, in a sequence similarity search (Supplementary Figure S1) all the A superfamily conotoxins belonging to the cysteine framework I [connectivity I–III, II–IV] show 40–88% identity to the known nAChR inhibitors (α-PIB, SrIA, SrIB, ArIA, ArIB, Ac1.1a, Ac1.1b, α-TxIA and TxIA(A10L)) belonging to the same gene superfamily with identical disulfide bridges and cysteine arrangement. Similarly, a sequence similarity search for PIVE and PIVF, A superfamily conotoxins belonging to cysteine framework IV [connectivity I–V, II–III, IV–VI] show 61–64% identity to the known nAChR inhibitors (OIVA and PeIVA). Both conotoxins also show 75% identity to the known NET/SLC6A2_inhibitor, Ar1311 (Figure 2). Norepinephrine transporter (NET) inhibitors have demonstrated efficacy in the treatment of children with attention-deficit hyperactivity disorder (ADHD) [72]. Additionally, the nAChR inhibitor Xen2174 (Mr1A) is in phase II clinical trials as a NET inhibitor tor the treatment of pain [73]. Thus PIVE and/or PIVF may have the potential to be developed into therapeutic drugs for the treatment of ADHD and/or pain.

Multiple alignment of A superfamily conotoxins belonging to cysteine framework IV predicted to target nAChR.

A superfamily conotoxins belonging to cysteine framework IV [connectivity I–V, II–III, IV–VI] (Ac4.2, Ac4.3a and Ac4.3b) also show 72–89% identity to known Na+ channel inhibitor, CcTx and 56–77% identity to K+ channel inhibitors, SIVA and MIVA. Thus, these conotoxins may be ideal candidates to increase understanding of interactions between the conotoxins and voltage- and ligand-gated ion channels (Figure 3). Other A superfamily conotoxins belonging to cysteine framework XIV [connectivity I–III, II–IV] show 78% (Ts14a) and 52–93% (As14b, As14a) identity to known K+ channel inhibitors Pu14a and vi11a, respectively. Sr11b and Sr11c, I2 superfamily conotoxins belonging to cysteine framework XI [connectivity I–IV, II–VI, III–VII, V–VIII] show 52–56% identity to K+ channel inhibitor, Sr11a and 43–52% identity to the calcium activated K+ channel inhibitor, BeTX (Supplementary Figure S1).

The sequence similarity search for conotoxins belonging to the T superfamily with cysteine framework V (Pu5.1, Pu5.4, Pu5.5, Pu5.6, Vi1359, Vi1361, Sr5.4, Sr5.5, Sr5.6 and Sr5.7) showed 40–75% identity to known Na+ channel inhibitor, Lt5d. A member of the M superfamily with cysteine arrangement III, Pr3b and a member of the I1 superfamily with cysteine framework XI, R11d, also showed 55% and 98% identity to known Na+ channel inhibitors, PIIIA and Fi11.6, respectively (Supplementary Figure S1). Whilst, De7b and Pr6a, both members of the O1 superfamily with cysteine framework VI/VII [connectivity I–IV, II–V, III–VI] show 70 and 46% identity to Ca2+ channel inhibitors, TxO1 and PnVIA, respectively. PnVIA in particular have been demonstrated to block dihydropyridine-insensitive high voltage-activated calcium channels [74]. This calcium channel type has demonstrated sensitivity to nonselective T-type calcium channel antagonists and has been shown to contribute to the functioning of small cerebral arteries [75]. Thus, we suggest that De7b, Pr6a or analogs of these particular conotoxins may render more effective treatment for therapy-refractory cerebrovascular constriction.

Multiple alignment of A superfamily conotoxins belonging to cysteine framework IV predicted to target both Na+ and K+ channels.

 4. Literature Analysis of Conotoxins Suggest Specific Therapeutic Potential

Curation of scientific literature draws attention to a similitude of neurodegenerative disorders (NDD) such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Multiple Sclerosis (MS) being characterized with aberrant neuronal excitability, caused by abnormal expression and function of ion channels.

AD is characterized by neuronal loss of the superficial cortex and synaptic alterations such as reduction of pre-synaptic terminal density [76]. Mousavi et al. demonstrated that decreased nAChR subtypes α4β2 and α7 activities plays vital roles in the progression of AD [23,77,78]. This finding has been supported by recent studies that demonstrate that Aβ peptides can directly and indirectly affect nAChR-mediated synaptic transmission [79] and that nAChR agonists increase sAPPα secretion whilst decreasing levels of Aβ peptides [80]. Increased intracellular Ca2+ has also been implicated in the pathogenesis of AD. Specifically, Kim et al. demonstrated that Aβ increases the activities of L-type Ca2+ channel subtype Cav1.2 and Cav1.3 [81] and a calcium channel blocker was shown to ameliorate AD [82]. Ye et al. additionally showed that activation of the large-conductance Ca2+-activated K+ (BK) channel depresses the basal synaptic transmission in the hippocampal CA1 area in APP (swe/ind) TgCRND8 mice [83]. This demonstration of activated BK channels in AD may likely be attributed to the impaired calcium homeostasis.

PD is characterized by a progressive loss of midbrain dopaminergic neurons and a subsequent reduction of striatal dopamine [84]. Perez et al. demonstrated that nAChR subtypes α4β2 and α6β2 are important modulators of dopaminergic transmission in the striatum and thus play a vital role in the progression of PD [85]. In addition, Kawamata et al. also demonstrated that nAChR subtypes α7 triggers multiple pathways that attenuate cytotoxicity in models of PD [86]. Ca2+ channels have also been implicated in the progression of PD, Tai et al. demonstrated that T-type Ca2+ channels are necessary for subthalamic burst firing and that pharmacological blockade of T-type Ca2+ channels reduces motor deficits in a rat model of PD [87]. Martel et al. further demonstrated that Kv1.2, Kv1.3 and Kv1.6 are key regulators in Dopamine release, the dysfunction of which is thought to be implicated in PD [33]. Since SK channels have been demonstrated to play an important role in modulating synaptic plasticity, dopaminergic neurotransmission, and learning and memory, recent reviews have focused on the contradictory roles of SK channels in modulating dopaminergic neurons in substantia nigra and whether modulation of SK channels could be a potential target for PD treatment [88].

MS is characterized by focal destruction of myelin sheaths, gliotic scars, and axonal damage [89]. Craner et al. demonstrated that Nav1.2 and Nav1.6 are distributed along extensive regions of demyelinated axons within acute MS plaques and that Nav1.6 which can be driven by persistent sodium current to import damaging levels of calcium into axons, is colocalized with Aβ, a marker of axonal injury, in acute MS lesions [90]. Craner et al. further demonstrated the distribution of Nav1.6 in microglia and macrophages in experimental autoimmune encephalomyelitis (EAE) and MS and its key role in their activation and phagocytosis. Additionally, treatment with a sodium channel blocker was shown to ameliorate neuroinflammatory disorder via anti-inflammatory mechanisms [91]. Similarly, Brand-Schieber and Werner demonstrated increased expression of L-type Ca2+ channel subtype Cav1.3 in mouse spinal cord axons and that calcium channel blockers ameliorated experimental autoimmune encephalomyelitis (EAE), an animal model of MS [92]. K+ channels have also been implicated in the pathogenesis of MS, as Wulff et al. demonstrated increased expression K+ channel subtype Kv1.3 in activated myelin-reactive T cells from patients with MS [93].

Since research findings demonstrate that drugs capable of altering the abnormal expression and function of the membrane ion channels characterizing the individual disease states have therapeutic potential [94]. We curated the ion channels associated with the progression of the above mentioned NDD and associated the curated ion channels with the recently identified conotoxins that have been demonstrated to target these ion channels (NDD→COMMON ION CHANNEL→CONOTOXIN) (Figure 4).

The schema represents potential links of NDD to the recently identified conotoxins based on the fact that these conotoxins target one of the ion channels associated with the pathogenesis of the NDD. AD and PD have been linked to two nAChR inhibitors (αD-cap and αD-mus) with cysteine arrangement -C-CC-C-CC-C-C-C-C- of the D superfamily and six nAChR inhibitors (SrIA, SrIB, ArIA, ArIB, α-TxIA and TxIA(A10L)) with the cysteine arrangement -CC-C-C- from the A superfamily. PD has additionally been linked to two K+ channel inhibitors (Sr11a and RIIIj) with the cysteine arrangements -CC-CC-C-C- and -CC-C-C-CC- of the I2 and M superfamilies, respectively. Whilst MS has been linked to three Na+ channel inhibitors (SIIIA, SIIIB and TIIIA) with the cysteine arrangement -CC-C-C-CC- of the M superfamily. AD and MS has also been linked to Ca2+ channel inhibitor (CalTx) since it has been demonstrated that CalTx inhibits L-type Ca2+ channel. However, it must be noted that it had not been demonstrated which specific L-type Ca2+ channel subtype is inhibited by CalTx. In summary, the selected conotoxins or analogs thereof may possess therapeutic potential in treatment of NDD.

Schematic representation linking neurodegenerative disorders (NDD) to conotoxins with therapeutic potential.

5. Concluding Remarks

Although the possible application of conotoxins to treat NDD have not been researched as extensively as analgesic applications, current scientific literature produced illustrates that several diverse conotoxin families have demonstrable potential for the treatment of NDD and that conotoxins targeting both voltage-gated and ligand-gated ion channel families have potential in treatment of NDD. With respect to the important physiological role of voltage- and ligand-gated ion channels in pain, inflammation and disease states, targeting specific relevant voltage- and ligand-gated ion channel subtypes could be an attractive pharmaceutical strategy, with conotoxins as promising drug development leads.

References Olivera B.M. Conus peptides: Biodiversity-based discovery and exogenomics J. Biol. Chem. 2006 281 31173 31177 10.1074/jbc.R600020200 Olivera B.M. Cruz L.J. Conotoxins, in retrospect Toxicon 2001 39 7 14 10.1016/S0041-0101(00)00157-4 Olivera B.M. Cruz L.J. de Santos V. LeCheminant G.W. Griffin D. Zeikus R. McIntosh J.M. Galyean R. Varga J. Gray W.R. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom Biochemistry 1987 26 2086 2090 10.1021/bi00382a0042441741 Safo P. Rosenbaum T. Shcherbatko A. Choi D.Y. Han E. Toledo-Aral J.J. Olivera B.M. Brehm P. Mandel G. Distinction among neuronal subtypes of voltage-activated sodium channels by mu-conotoxin piiia J. Neurosci. 2000 20 76 80 10627583 Catterall W.A. Goldin A.L. Waxman S.G. International union of pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels Pharmacol. Rev. 2005 57 397 409 10.1124/pr.57.4.4 Ichida S. Abe J. Zhang Y.A. Sugihara K. Imoto K. Wada T. Fujita N. Sohma H. Characteristics of the inhibitory effect of calmodulin on specific [125i]omega-conotoxin GVIA binding to crude membranes from chick brain Neurochem. Res. 2000 25 1629 1635 10.1023/A:1026674721542 Olivera B.M. Miljanich G.P. Ramachandran J. Adams M.E. Calcium channel diversity and neurotransmitter release: The omega-conotoxins and omega-agatoxins Annu. Rev. Biochem. 1994 63 823 867 10.1146/annurev.bi.63.070194.004135 Sher E. Gotti C. Canal N. Scoppetta C. Piccolo G. Evoli A. Clementi F. Specificity of calcium channel autoantibodies in lambert-eaton myasthenic syndrome Lancet 1989 2 640 643 2570899 Bowersox S.S. Luther R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus Toxicon 1998 36 1651 1658 10.1016/S0041-0101(98)00158-5 Barton M.E. White H.S. Wilcox K.S. The effect of CGX-1007 and CI-1041, novel nmda receptor antagonists, on NMDA receptor-mediated EPSCs Epilepsy Res. 2004 59 13 24 10.1016/j.eplepsyres.2003.12.011 Craig A.G. Norberg T. Griffin D. Hoeger C. Akhtar M. Schmidt K. Low W. Dykert J. Richelson E. Navarro V. Contulakin-G, an O-glycosylated invertebrate neurotensin J. Biol. Chem. 1999 274 13752 13759 10.1074/jbc.274.20.1375210318778 Kern S.E. Allen J. Wagstaff J. Shafer S.L. Yaksh T. The pharmacokinetics of the conopeptide contulakin-G (CGX-1160) after intrathecal administration: An analysis of data from studies in beagles Anesth. Analg. 2007 104 1514 1520 10.1213/01.ane.0000262038.58546.e6 Lubbers N.L. Campbell T.J. Polakowski J.S. Bulaj G. Layer R.T. Moore J. Gross G.J. Cox B.F. Postischemic administration of CGX-1051, a peptide from cone snail venom, reduces infarct size in both rat and dog models of myocardial ischemia and reperfusion J. Cardiovasc. Pharmacol. 2005 46 141 146 10.1097/01.fjc.0000167015.84715.27 Livett B.G. Sandall D.W. Keays D. Down J. Gayler K.R. Satkunanathan N. Khalil Z. Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor Toxicon 2006 48 810 829 10.1016/j.toxicon.2006.07.023 Nielsen C.K. Lewis R.J. Alewood D. Drinkwater R. Palant E. Patterson M. Yaksh T.L. McCumber D. Smith M.T. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain Pain 2005 118 112 124 10.1016/j.pain.2005.08.002 Obata H. Conklin D. Eisenach J.C. Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats Pain 2005 113 271 276 10.1016/j.pain.2004.10.017 Yan L.D. Liu Y.L. Zhang L. Dong H.J. Zhou P.L. Su R.B. Gong Z.H. Huang P.T. Spinal antinociception of synthetic omega-conotoxin SO-3, a selective N-type neuronal voltage-sensitive calcium channel blocker, and its effects on morphine analgesia in chemical stimulus tests in rodent Eur. J. Pharmacol. 2010 636 73 81 10.1016/j.ejphar.2010.03.036 Gasior M. White N.A. Rogawski M.A. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA J. Pharmacol. Exp. Ther. 2007 323 458 468 10.1124/jpet.107.125047 Shahlaie K. Lyeth B.G. Gurkoff G.G. Muizelaar J.P. Berman R.F. Neuroprotective effects of selective N-type VGCC blockade on stretch-injury-induced calcium dynamics in cortical neurons J. Neurotrauma 2010 27 175 187 10.1089/neu.2009.1003 Chen P. Dendorfer A. Finol-Urdaneta R.K. Terlau H. Olivera B.M. Biochemical characterization of kappam-RIIIJ, a Kv1.2 channel blocker: Evaluation of cardioprotective effects of kappam-conotoxins J. Biol. Chem. 2010 285 14882 14889 10.1074/jbc.M109.06848620220134 Lahiry A. Dave K. Conotoxins: Review and docking studies to determine potentials of conotoxin as an anticancer drug molecule Curr. Top. Med. Chem. 2012 in press. Waxman S.G. Axonal conduction and injury in multiple sclerosis: The role of sodium channels Nat. Rev. Neurosci. 2006 7 932 941 10.1038/nrn2023 Haydar S.N. Dunlop J. Neuronal nicotinic acetylcholine receptors—Targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer’s disease Curr. Top. Med. Chem. 2010 10 144 152 10.2174/156802610790410983 Sayers E.W. Barrett T. Benson D.A. Bolton E. Bryant S.H. Canese K. Chetvernin V. Church D.M. Dicuccio M. Federhen S. Database resources of the national center for biotechnology information Nucleic Acids Res. 2010 38 D5 D16 10.1093/nar/gkp96719910364 French R.J. Terlau H. Sodium channel toxins—Receptor targeting and therapeutic potential Curr. Med. Chem. 2004 11 3053 3064 10.2174/092986704336386615578999 Wood J.N. Boorman J.P. Okuse K. Baker M.D. Voltage-gated sodium channels and pain pathways J. Neurobiol. 2004 61 55 71 10.1002/neu.20094 Cox J.J. Reimann F. Nicholas A.K. Thornton G. Roberts E. Springell K. Karbani G. Jafri H. Mannan J. Raashid Y. An SCN9A channelopathy causes congenital inability to experience pain Nature 2006 444 894 898 10.1038/nature0541317167479 Xu R. Thomas E.A. Jenkins M. Gazina E.V. Chiu C. Heron S.E. Mulley J.C. Scheffer I.E. Berkovic S.F. Petrou S. A childhood epilepsy mutation reveals a role for developmentally regulated splicing of a sodium channel Mol. Cell. Neurosci. 2007 35 292 301 10.1016/j.mcn.2007.03.003 Catterall W.A. Kalume F. Oakley J.C. Nav1.1 channels and epilepsy J. Physiol. 2010 588 1849 1859 10.1113/jphysiol.2010.187484 Gutman G.A. Chandy K.G. Grissmer S. Lazdunski M. McKinnon D. Pardo L.A. Robertson G.A. Rudy B. Sanguinetti M.C. Stuhmer W. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels Pharmacol. Rev. 2005 57 473 508 10.1124/pr.57.4.10 Mani B.K. Brueggemann L.I. Cribbs L.L. Byron K.L. Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery Br. J. Pharmacol. 2011 164 237 249 10.1111/j.1476-5381.2011.01273.x Takeda M. Tanimoto T. Nasu M. Matsumoto S. Temporomandibular joint inflammation decreases the voltage-gated K+ channel subtype 1.4-immunoreactivity of trigeminal ganglion neurons in rats Eur. J. Pain 2008 12 189 195 10.1016/j.ejpain.2007.04.005 Martel P. Leo D. Fulton S. Berard M. Trudeau L.E. Role of Kv1 potassium channels in regulating dopamine release and presynaptic D2 receptor function PLoS One 2011 6 Cahalan M.D. Chandy K.G. Ion channels in the immune system as targets for immunosuppression Curr. Opin. Biotechnol. 1997 8 749 756 10.1016/S0958-1669(97)80130-9 Yuan H. Wang W.P. Feng N. Wang L. Wang X.L. Donepezil attenuated oxygen-glucose deprivation insult by blocking Kv2.1 potassium channels Eur. J. Pharmacol. 2011 657 76 83 10.1016/j.ejphar.2011.01.054 MacDonald P.E. Sewing S. Wang J. Joseph J.W. Smukler S.R. Sakellaropoulos G. Wang J. Saleh M.C. Chan C.B. Tsushima R.G. Inhibition of Kv2.1 voltage-dependent K+ channels in pancreatic beta-cells enhances glucose-dependent insulin secretion J. Biol. Chem. 2002 277 44938 44945 10.1074/jbc.M20553220012270920 Ellison D.H. The voltage-gated K+ channel subunit Kv1.1 links kidney and brain J. Clin. Invest. 2009 119 763 766 10.1172/JCI38835 Su X. Leon L.A. Laping N.J. Role of spinal Cav2.2 and Cav2.1 ion channels in bladder nociception J. Urol. 2008 179 2464 2469 10.1016/j.juro.2008.01.088 Ilijic E. Guzman J.N. Surmeier D.J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease Neurobiol. Dis. 2011 43 364 371 10.1016/j.nbd.2011.04.007 Wildburger N.C. Lin-Ye A. Baird M.A. Lei D. Bao J. Neuroprotective effects of blockers for T-type calcium channels Mol. Neurodegener. 2009 4 Jing X. Li D.Q. Olofsson C.S. Salehi A. Surve V.V. Caballero J. Ivarsson R. Lundquist I. Pereverzev A. Schneider T. Cav2.3 calcium channels control second-phase insulin release J. Clin. Invest. 2005 115 146 154 15630454 Liu J. Wu Q. Pi C. Zhao Y. Zhou M. Wang L. Chen S. Xu A. Isolation and characterization of a T-superfamily conotoxin from Conus litteratus with targeting tetrodotoxin-sensitive sodium channels Peptides 2007 28 2313 2319 10.1016/j.peptides.2007.09.006 Wang L. Pi C. Liu J. Chen S. Peng C. Sun D. Zhou M. Xiang H. Ren Z. Xu A. Identification and characterization of a novel O-superfamily conotoxin from Conus litteratus J. Pept. Sci. 2008 14 1077 1083 10.1002/psc.1044 Lewis R.J. Schroeder C.I. Ekberg J. Nielsen K.J. Loughnan M. Thomas L. Adams D.A. Drinkwater R. Adams D.J. Alewood P.F. Isolation and structure-activity of mu-conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels Mol. Pharmacol. 2007 71 676 685 17142296 Gilly W.F. Richmond T.A. Duda T.F. Jr. Elliger C. Lebaric Z. Schulz J. Bingham J.P. Sweedler J.V. A diverse family of novel peptide toxins from an unusual cone snail, Conus californicus J. Exp. Biol. 2011 214 147 161 10.1242/jeb.04608621147978 Holford M. Zhang M.M. Gowd K.H. Azam L. Green B.R. Watkins M. Ownby J.P. Yoshikami D. Bulaj G. Olivera B.M. Pruning nature: Biodiversity-derived discovery of novel sodium channel blocking conotoxins from Conus bullatus Toxicon 2009 53 90 98 10.1016/j.toxicon.2008.10.017 Schroeder C.I. Ekberg J. Nielsen K.J. Adams D. Loughnan M.L. Thomas L. Adams D.J. Alewood P.F. Lewis R.J. Neuronally micro-conotoxins from Conus striatus utilize an alpha-helical motif to target mammalian sodium channels J. Biol. Chem. 2008 283 21621 21628 10.1074/jbc.M80285220018522941 Lee S. Kim Y. Back S.K. Choi H.W. Lee J.Y. Jung H.H. Ryu J.H. Suh H.W. Na H.S. Kim H.J. Analgesic effect of highly reversible omega-conotoxin fvia on N type Ca2+ channels Mol. Pain 2010 6 Bernaldez J. Lopez O. Licea A. Salceda E. Arellano R.O. Vega R. Soto E. Electrophysiological characterization of a novel small peptide from the venom of Conus californicus that targets voltage-gated neuronal Ca2+ channels Toxicon 2011 57 60 67 10.1016/j.toxicon.2010.09.015 Aguilar M.B. Lopez-Vera E. de la Cotera E.P.H. Falcon A. Olivera B.M. Maillo M. I-conotoxins in vermivorous species of the west atlantic: Peptide sr11a from Conus spurius Peptides 2007 28 18 23 10.1016/j.peptides.2006.08.024 Aguilar M.B. Perez-Reyes L.I. Lopez Z. de la Cotera E.P.H. Falcon A. Ayala C. Galvan M. Salvador C. Escobar L.I. Peptide sr11a from Conus spurius is a novel peptide blocker for Kv1 potassium channels Peptides 2010 31 1287 1291 10.1016/j.peptides.2010.04.007 Quik M. Wonnacott S. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson’s disease Pharmacol. Rev. 2011 63 938 966 10.1124/pr.110.003269 Tong M. Arora K. White M.M. Nichols R.A. Role of key aromatic residues in the ligand-binding domain of α7 nicotinic receptors in the agonist action of β-amyloid J. Biol. Chem. 2011 286 34373 34381 10.1074/jbc.M111.24129921828053 Marquis K.L. Comery T.A. Jow F. Navarra R.L. Grauer S.M. Pulicicchio C. Kelley C. Brennan J.A. Roncarati R. Scali C. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625 Psychopharmacology (Berl.) 2011 218 635 647 10.1007/s00213-011-2357-6 Raffa R.B. Cancer “survivor-care”: I. The alpha7 nachr as potential target for chemotherapy-related cognitive impairment J. Clin. Pharm. Ther. 2010 36 437 445 10.1111/j.1365-2710.2010.01208.x Vincler M. Wittenauer S. Parker R. Ellison M. Olivera B.M. McIntosh J.M. Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors Proc. Natl. Acad. Sci. USA 2006 103 17880 17884 10.1073/pnas.060871510317101979 Kauferstein S. Kendel Y. Nicke A. Coronas F.I. Possani L.D. Favreau P. Krizaj I. Wunder C. Kauert G. Mebs D. New conopeptides of the D-superfamily selectively inhibiting neuronal nicotinic acetylcholine receptors Toxicon 2009 54 295 301 10.1016/j.toxicon.2009.04.016 Loughnan M. Nicke A. Jones A. Schroeder C.I. Nevin S.T. Adams D.J. Alewood P.F. Lewis R.J. Identification of a novel class of nicotinic receptor antagonists: Dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus vexillu J. Biol. Chem. 2006 281 24745 24755 10.1074/jbc.M60370320016790424 Jimenez E.C. Olivera B.M. Teichert R.W. Alphac-conotoxin PrXA: A new family of nicotinic acetylcholine receptor antagonists Biochemistry 2007 46 8717 8724 10.1021/bi700582m Lluisma A.O. Lopez-Vera E. Bulaj G. Watkins M. Olivera B.M. Characterization of a novel psi-conotoxin from Conus parius reeve Toxicon 2008 51 174 180 10.1016/j.toxicon.2007.07.009 Shon K.J. Grilley M. Jacobsen R. Cartier G.E. Hopkins C. Gray W.R. Watkins M. Hillyard D.R. Rivier J. Torres J. A noncompetitive peptide inhibitor of the nicotinic acetylcholine receptor from Conus purpurascens venom Biochemistry 1997 36 9581 9587 10.1021/bi970235w9236004 Peng C. Ye M. Wang Y. Shao X. Yuan D. Liu J. Hawrot E. Wang C. Chi C. A new subfamily of conotoxins belonging to the A-superfamily Peptides 2010 31 2009 2016 10.1016/j.peptides.2010.07.01120691232 Lopez-Vera E. Jacobsen R.B. Ellison M. Olivera B.M. Teichert R.W. A novel alpha conotoxin (alpha-PIB) isolated from C. purpurascens is selective for skeletal muscle nicotinic acetylcholine receptors Toxicon 2007 49 1193 1199 10.1016/j.toxicon.2007.02.007 Lopez-Vera E. Aguilar M.B. Schiavon E. Marinzi C. Ortiz E. Restano Cassulini R. Batista C.V. Possani L.D. de la Cotera E.P.H. Peri F. Novel alpha-conotoxins from Conus spurius and the alpha-conotoxin ei share high-affinity potentiation and low-affinity inhibition of nicotinic acetylcholine receptors FEBS J. 2007 274 3972 3985 10.1111/j.1742-4658.2007.05931.x17635581 Park K.H. Suk J.E. Jacobsen R. Gray W.R. McIntosh J.M. Han K.H. Solution conformation of alpha-conotoxin EI, a neuromuscular toxin specific for the alpha 1/delta subunit interface of torpedo nicotinic acetylcholine receptor J. Biol. Chem. 2001 276 49028 49033 10.1074/jbc.M10779820011641403 Yuan D.D. Han Y.H. Wang C.G. Chi C.W. From the identification of gene organization of alpha conotoxins to the cloning of novel toxins Toxicon 2007 49 1135 1149 10.1016/j.toxicon.2007.02.011 Liu L. Chew G. Hawrot E. Chi C. Wang C. Two potent alpha3/5 conotoxins from piscivorous Conus achatinus Acta Biochim. Biophys. Sin. (Shanghai) 2007 39 438 444 10.1111/j.1745-7270.2007.00301.x Whiteaker P. Christensen S. Yoshikami D. Dowell C. Watkins M. Gulyas J. Rivier J. Olivera B.M. McIntosh J.M. Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist Biochemistry 2007 46 6628 6638 10.1021/bi700420217497892 Dutertre S. Ulens C. Buttner R. Fish A. van Elk R. Kendel Y. Hopping G. Alewood P.F. Schroeder C. Nicke A. Achbp-targeted alpha-conotoxin correlates distinct binding orientations with nachr subtype selectivity EMBO J. 2007 26 3858 3867 10.1038/sj.emboj.7601785 Johnson M. Zaretskaya I. Raytselis Y. Merezhuk Y. McGinnis S. Madden T.L. NCBI BLAST: A better web interface Nucleic Acids Res. 2008 36 W5 W9 10.1093/nar/gkn201 Larkin M.A. Blackshields G. Brown N.P. Chenna R. McGettigan P.A. McWilliam H. Valentin F. Wallace I.M. Wilm A. Lopez R. Clustal W and clustal X version 2.0 Bioinformatics 2007 23 2947 2948 10.1093/bioinformatics/btm40417846036 Ramoz N. Boni C. Downing A.M. Close S.L. Peters S.L. Prokop A.M. Allen A.J. Hamon M. Purper-Ouakil D. Gorwood P. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD) Neuropsychopharmacology 2009 34 2135 2142 10.1038/npp.2009.39 Brust A. Palant E. Croker D.E. Colless B. Drinkwater R. Patterson B. Schroeder C.I. Wilson D. Nielsen C.K. Smith M.T. chi-Conopeptide pharmacophore development: Toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain J. Med. Chem. 2009 52 6991 7002 10.1021/jm900341319860431 Kits K.S. Lodder J.C. van der Schors R.C. Li K.W. Geraerts W.P. Fainzilber M. Novel omega-conotoxins block dihydropyridine-insensitive high voltage-activated calcium channels in molluscan neurons J. Neurochem. 1996 67 2155 2163 8863526 Kuo I.Y. Ellis A. Seymour V.A. Sandow S.L. Hill C.E. Dihydropyridine-insensitive calcium currents contribute to function of small cerebral arteries J. Cereb. Blood Flow Metab. 2010 30 1226 1239 10.1038/jcbfm.2010.11 Cummings J.L. Vinters H.V. Cole G.M. Khachaturian Z.S. Alzheimer’s disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities Neurology 1998 51 S2 S17 discussion S65–S17. 9851723 Mousavi M. Hellstrom-Lindahl E. Guan Z.Z. Shan K.R. Ravid R. Nordberg A. Protein and mrna levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer’s disease Neuroscience 2003 122 515 520 10.1016/S0306-4522(03)00460-3 Yuan D.D. Liu L. Shao X.X. Peng C. Chi C.W. Guo Z.Y. New conotoxins define the novel I3-superfamily Peptides 2009 30 861 865 10.1016/j.peptides.2009.01.012 Srivareerat M. Tran T.T. Salim S. Aleisa A.M. Alkadhi K.A. Chronic nicotine restores normal abeta levels and prevents short-term memory and e-ltp impairment in abeta rat model of Alzheimer’s disease Neurobiol. Aging 2011 32 834 844 10.1016/j.neurobiolaging.2009.04.015 Mousavi M. Hellstrom-Lindahl E. Nicotinic receptor agonists and antagonists increase sappalpha secretion and decrease abeta levels in vitro Neurochem. Int. 2009 54 237 244 10.1016/j.neuint.2008.12.001 Kim S. Rhim H. Effects of amyloid-beta peptides on voltage-gated l-type Cav1.2 and Cav1.3 Ca2+ channels Mol. Cells 2011 32 289 294 10.1007/s10059-011-0075-x Anekonda T.S. Quinn J.F. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: The case for isradipine Biochim. Biophys. Acta 2011 1812 1584 1590 10.1016/j.bbadis.2011.08.01321925266 Ye H. Jalini S. Mylvaganam S. Carlen P. Activation of large-conductance Ca2+-activated K+ channels depresses basal synaptic transmission in the hippocampal CA1 area in APP (swe/ind) TgCRND8 mice Neurobiol. Aging 2010 31 591 604 10.1016/j.neurobiolaging.2008.05.012 Meyer A.K. Maisel M. Hermann A. Stirl K. Storch A. Restorative approaches in Parkinson’s disease: Which cell type wins the race? J. Neurol. Sci. 2010 289 93 103 10.1016/j.jns.2009.08.024 Perez X.A. Bordia T. McIntosh J.M. Quik M. Alpha6ss2* and alpha4ss2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: Relevance to Parkinson’s disease Mol. Pharmacol. 2010 78 971 980 10.1124/mol.110.067561 Kawamata J. Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer’s and Parkinson’s diseases J. Alzheimers Dis. 2011 24 95 109 21403387 Tai C.H. Yang Y.C. Pan M.K. Huang C.S. Kuo C.C. Modulation of subthalamic T-type Ca2+ channels remedies locomotor deficits in a rat model of Parkinson disease J. Clin. Invest. 2011 121 3289 3305 10.1172/JCI46482 Liu X.K. Wang G. Chen S.D. Modulation of the activity of dopaminergic neurons by SK channels: A potential target for the treatment of Parkinson’s disease? Neurosci. Bull. 2010 26 265 271 10.1007/s12264-010-1217-4 Compston A. Coles A. Multiple sclerosis Lancet 2008 372 1502 1517 10.1016/S0140-6736(08)61620-7 Craner M.J. Newcombe J. Black J.A. Hartle C. Cuzner M.L. Waxman S.G. Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger Proc. Natl. Acad. Sci. USA 2004 101 8168 8173 10.1073/pnas.040276510115148385 Craner M.J. Damarjian T.G. Liu S. Hains B.C. Lo A.C. Black J.A. Newcombe J. Cuzner M.L. Waxman S.G. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS Glia 2005 49 220 229 10.1002/glia.20112 Brand-Schieber E. Werner P. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis Exp. Neurol. 2004 189 5 9 10.1016/j.expneurol.2004.05.023 Wulff H. Calabresi P.A. Allie R. Yun S. Pennington M. Beeton C. Chandy K.G. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS J. Clin. Invest. 2003 111 1703 1713 12782673 Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models Biol. Pharm. Bull. 2009 32 332 336 10.1248/bpb.32.33219252273 Supplementary Files

PDF-Document (PDF, 2369 KB)